Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
Microorganisms in Medicine and Therapeutics01:29

Microorganisms in Medicine and Therapeutics

Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
Satellite Stem Cells and Muscular Dystrophy01:21

Satellite Stem Cells and Muscular Dystrophy

Satellite stem cells or myosatellite cells are quiescent stem cells that Alexander Mauro first identified in 1961. These cells are located between the sarcolemma, the plasma membrane of muscle fibers, and the basal lamina, the connective tissue sheath covering it. These mononucleated cells are activated in response to muscle injury, can transform into myoblasts, and may form or repair muscle fibers. Myosatellite cells can provide additional myonuclei for muscle regeneration or return to a...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clinical validation of a novel in vitro diagnostic neurofilament light chain assay for the prognostication of disease activity in people with relapsing multiple sclerosis.

Multiple sclerosis (Houndmills, Basingstoke, England)·2025
Same author

AI-driven reclassification of multiple sclerosis progression.

Nature medicine·2025
Same author

Targeting the neonatal Fc receptor (FcRn) is not beneficial in an animal model of chronic neuritis.

Immunologic research·2024
Same author

Prognostic factors for worsening and improvement in multiple sclerosis using a multistate model.

Multiple sclerosis (Houndmills, Basingstoke, England)·2024
Same author

Temporal Relationship Between Serum Neurofilament Light Chain and Radiologic Disease Activity in Patients With Multiple Sclerosis.

Neurology·2024
Same author

A review of Bruton's tyrosine kinase inhibitors in multiple sclerosis.

Therapeutic advances in neurological disorders·2024

Related Experiment Video

Updated: Jun 20, 2026

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
09:38

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

The future of multiple sclerosis therapy.

Bernd C Kieseier1, Heinz Wiendl, Hans-Peter Hartung

  • 1Department of Neurology, Heinrich-Heine University, Moorenstrasse 5, 40225 Duesseldorf, Germany. bernd.kieseier@uni-duesseldorf.de

Pharmacological Research
|September 1, 2009
PubMed
Summary

New multiple sclerosis (MS) therapies are emerging, including oral medications and potent monoclonal antibodies. While current treatments show partial effectiveness, ongoing research aims to improve outcomes for this common neurological disorder.

More Related Videos

Two-photon Imaging of Cellular Dynamics in the Mouse Spinal Cord
10:44

Two-photon Imaging of Cellular Dynamics in the Mouse Spinal Cord

Published on: February 22, 2015

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis
06:19

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis

Published on: September 9, 2022

Related Experiment Videos

Last Updated: Jun 20, 2026

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
09:38

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

Two-photon Imaging of Cellular Dynamics in the Mouse Spinal Cord
10:44

Two-photon Imaging of Cellular Dynamics in the Mouse Spinal Cord

Published on: February 22, 2015

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis
06:19

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis

Published on: September 9, 2022

Area of Science:

  • Neuroimmunology
  • Neurology

Background:

  • Multiple sclerosis (MS) is a primary inflammatory autoimmune disease of the central nervous system.
  • It is a leading cause of neurological disability in young adults, characterized by significant heterogeneity.
  • Recent advancements in understanding MS immunopathology have spurred novel therapeutic development.

Purpose of the Study:

  • To review and contextualize recent advances in multiple sclerosis therapeutics.
  • To highlight emerging treatment strategies, including oral formulations and monoclonal antibodies.
  • To address unmet needs in MS management.

Main Methods:

  • Critical review of pivotal and preliminary reports on new MS therapies.
  • Analysis of developments in oral therapies for MS.
  • Evaluation of novel monoclonal antibody treatments and their safety profiles.

Main Results:

  • Therapeutic approaches for MS have evolved significantly, with more aggressive treatment of relapsing forms.
  • Partially effective disease-modifying drugs are currently available, but unmet needs persist.
  • Promising advancements include the development of oral MS therapies and potent monoclonal antibodies with varying efficacy and side effect profiles.

Conclusions:

  • The development of oral therapies and potent monoclonal antibodies represents significant progress in MS treatment.
  • While current treatments offer partial efficacy, further research is crucial to address remaining challenges.
  • Future therapeutic strategies focus on improving effectiveness and safety for managing multiple sclerosis.